Jeevan Scientific Technology is an independent clinical testing partner - the company that generic drug makers and biotech firms hire to prove their medicines work the same as the original, so regulators will let them sell. It started in 1999 as a small IT firm in Hyderabad, but pivoted decisively in 2014, building a full-service clinical research platform around a core of bioavailability and bioequivalence (BA/BE) studies - the tests that show a generic pill releases its active ingredient into the bloodstream just like the branded one. The recurring approach is to own the entire testing chain under one roof - from recruiting volunteers and running the clinic to analysing blood samples in its own lab - and to make that chain so audit-ready that regulators from the US, Europe, and India keep giving it the stamps that bring in the next client. # Business segments Two engines at different stages - a clinical research cash cow that has cleared over a dozen international regulatory inspections, and an early-stage bet on drug ingredients and delivery technology, both built around the same Hyderabad laboratory core. ## 1. Clinical Research Services: the testing engine that gets generic drugs approved **A one-stop shop where pharmaceutical companies outsource the human trials and lab work needed to prove a generic drug is equivalent to the original - and where a clean regulatory track record is the product itself.** - **The core product is a BA/BE study** - when a drug maker wants to launch a generic version, JSTL runs a controlled trial on healthy volunteers, measuring how the drug behaves in the bloodstream, and delivers a report that regulators like the USFDA use to decide on approval. - **A 132-bed clinic in Hyderabad does the heavy lifting** - the clinical pharmacology centre runs four separate units with a combined 132 beds, plus emergency care, a temperature-controlled pharmacy, and a tie-up with nearby hospitals, letting it run 150-200 studies a year at peak. - **The bioanalytical lab is the invisible factory** - 12 LC-MS/MS machines, including two sensitive enough for complex hormones and biologics, analyse blood samples from every study under Good Laboratory Practice standards, and the facility has room to double that instrument count. - **Regulatory approvals are the moat** - the clinical facility and lab have together passed roughly 16 inspections from the USFDA, WHO, UK-MHRA, and Indian CDSCO, including a USFDA audit with zero observations in FY20 and a 2024 approval from Oman’s health ministry valid through 2028. - **Services stretch from first-in-human to post-approval monitoring** - beyond BA/BE, the company’s clinical trials team has experience in various phases of clinical projects and plans to enhance capability in interventional trials, alongside pharmacovigilance (drug safety monitoring after a medicine is on the market), medical writing, and biostatistics, often bundled as an end-to-end package for the same client. ## 2. Nayas Laboratories and Naya Pharma: a bet on owning the molecule, not just testing it **Two young subsidiaries - one designing novel drug-delivery polymers, the other gearing up to manufacture active pharmaceutical ingredients - that aim to capture work upstream of the clinical testing engine.** - **Nayas Laboratories designs how a drug gets released** - acquired in early 2023 with an 89% stake, it specialises in advanced drug delivery platforms and patentable biomedical polymers, targeting complex generics and 505(b)(2) drugs (modified versions of existing approved drugs) from concept to commercialisation. - **Naya Pharma will make the raw chemical ingredients** - approved for acquisition in late 2025 with a 60% stake, it was set up to manufacture Active Pharmaceutical Ingredients and intermediates, with JSTL committing up to Rs. 120 crores in investment, loans, and guarantees to fund a state-of-the-art R&D and manufacturing lab. # Group structure and partners **A Hyderabad-headquartered parent with two early-stage subsidiaries, after a clean exit from a decade-old IT services division.** - JSTL is the listed parent, promoted and run by the Kishore-Vanaja family, with Ms. M. Snigdha as CEO and Executive Director. - Nayas Laboratories (89% stake, acquired February 2023) is a formulation R&D CRO that entered a 50:50 co-development agreement with Aditri Pharma Sciences in October 2023 to develop certain pharmaceutical preparations. - Naya Pharma (60% stake, approved December 2025) is a pre-revenue API manufacturer that had nil turnover in the three years before the acquisition and a net worth of about Rs. 2.4 crores as of FY24. - The company previously owned two IT services subsidiaries - Enhops Solutions in India and Enhops Inc. in the US - but sold them in early 2022 to an unrelated buyer for Rs. 13.14 crores, exiting the IT segment entirely to focus on clinical research.